Copy/Paste the key inputs from the product brochure, per guidance from Marketing.
Stargardt disease (STGD) is a monogenic disease characterized by retinal dystrophy and macular degeneration that results in progressive loss of vision. In contrast to many other forms of macular degeneration or retinal dystrophy, STGD typically strikes patients in early adulthood. Despite the severity of the disease and the tremendous burden it inflicts on patients, there are no therapies approved to treat STGD. Although VEGF inhibitors (Avastin, Eylea, Lucentis) are prescribed off-label on rare occasions, there is no clinical evidence from prospective trials that the agents are effective in STGD. However, several therapies with novel mechanisms of action are in development to treat STGD and, if efficacious, stand to capitalize on the immense unmet need for effective therapies in this space.
What are the key areas of unmet need and opportunity in the STGD market?
What is the approximate size of the diagnosed STGD population in the United States? How are pediatric and adult cases of STGD segmented by visual acuity?
What is the expected impact of novel therapy launches, especially drugs with novel mechanisms of action?
How does each current and future player influence the market and how will this change in the future?
What are the key drivers and limiters of the STGD market?
Geography: United States
Primary Research: Three KOL interviews in April 2019
Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.
Ian Love, Ph.D., is an analyst on the Infectious, Niche, and Rare Diseases team at DRG, part of Clarivate. Prior to joining DRG, he was an instructor in the Department of Internal Medicine at Virginia Commonwealth University. He received his doctorate in biomedical sciences from the University of Massachusetts Medical School and his B.S. in cell and molecular biology from Worcester Polytechnic Institute.
Narendra Parihar, M.P.H., is a principal epidemiologist at Clarivate. His areas of interest are cancer epidemiology, rare disease epidemiology, and targeted therapies in cancer. A former dentist, he earned his M.P.H. from the Tata Institute of Social Sciences in Mumbai.